VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 3, 2026
Stock Comparison
ASSA ABLOY AB vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
ASSA ABLOY AB
ASSA-B · Nasdaq Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into ASSA ABLOY AB's moat claims, evidence, and risks.
View ASSA-B analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: ASSA ABLOY AB leads (76 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: ASSA ABLOY AB has 5 segments (32.9% in Entrance Systems); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Moat breadth: ASSA ABLOY AB has 4 moat types across 2 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
ASSA ABLOY AB
Entrance Systems
Entrance automation and industrial door solutions (pedestrian automatic doors, industrial doors, loading dock equipment, service/maintenance)
Global
Commercial/industrial facilities via distributors, installers and service channels
OEM + service/maintenance provider
32.9%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
ASSA ABLOY AB strengths
Bristol-Myers Squibb Company strengths
Segment mix
ASSA ABLOY AB segments
Full profile >Opening Solutions EMEIA
Oligopoly
Opening Solutions Americas
Oligopoly
Opening Solutions Asia Pacific
Competitive
Global Technologies
Oligopoly
Entrance Systems
Oligopoly
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.